Dennis Brooks
Interventional Cardiology · Ventura, CANPI 1376547299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,898 and has fallen 98.9% since, to $21 in 2024. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 201 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$579
- Amgen$436
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$417
- Johnson & Johnson$302
- Pfizer$240
- Amarin Pharma, Inc.$167
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,508100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $579 |
| Amgen | 23 | $436 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $417 |
| Johnson & Johnson | 19 | $302 |
| Pfizer | 21 | $240 |
| Amarin Pharma, Inc. | 8 | $167 |
| Kowa Pharmaceuticals America, Inc. | 5 | $148 |
| Gilead | 18 | $136 |
| Boehringer Ingelheim | 6 | $120 |
| Esperion Therapeutics, Inc. | 5 | $99 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Actelion Pharmaceuticals US, Inc. | 4 | $80 |
| AstraZeneca | 4 | $78 |
| Boston Scientific | 3 | $75 |
| Sanofi-aventis U.S. LLC | 3 | $66 |
| Edwards Lifesciences | 3 | $60 |
| Chiesi USA, Inc. | 2 | $57 |
| Medtronic(2 entities) | 2 | $39 |
| Merck | 2 | $37 |
| Cvrx, Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Braemar Manufacturing, LLC | 1 | $33 |
| Biosense Webster, Inc. | 1 | $29 |
| Irhythm Technologies, Inc. | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $25 |
| Cardiva Medical, Inc. | 1 | $23 |
| Cathworks, Inc. | 1 | $21 |
| Biotronik Inc. | 1 | $21 |
| Abbott | 1 | $16 |
How this compares
$3,516 in reported general payments places this provider in the 30th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Ventura
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.